logo-loader
viewImmuPharma PLC

ImmuPharma shares start trading on Euronext Growth Brussels

The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares with European investors, the group said.

ImmuPharma PLC -
ImmuPharma noted that the new listing does not affect its trading on London's AIM, nor is there any intention from the firm to raise additional funds from either AIM or Euronext

ImmuPharma PLC (LON:IMM) said its shares began trading on the Euronext Growth Brussels (Euronext) exchange today (Thursday) under the ticker 'ALIMM'.

The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares with European investors, the specialty biopharmaceutical group said in  a brief statement.

READ: ImmuPharma says shares will be dual-listed on Euronext Growth Brussels with effect from 19 December

The move is also aligned with the group's investment thesis for ImmuPharma and specifically Lupuzor being repositioned, following the firm's recent deal with US Avion Pharmaceuticals, which is funding an international Phase III trial for ImmuPharma's lead programme, Lupuzor.

"ImmuPharma looks forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US," the company said.

ImmuPharma noted that the new listing does not affect  its trading on London's AIM, nor is there any intention from the firm to raise additional funds from either AIM or Euronext.

Quick facts: ImmuPharma PLC

Price: 14.5 GBX

AIM:IMM
Market: AIM
Market Cap: £26.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Immupharma chairman 'delighted' with first significant investment from...

ImmuPharma PLC's (LON:IMM) Tim McCarthy speaks to Proactive London's Andrew Scott following the news of new funding through two specialist US healthcare investors. Up to US$6.3mln is being invested into IMM from an issue of unsecured convertible securities and associated options to L1 Capital...

on 15/6/20

2 min read